FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157782313> ?p ?o ?g. }

• W2157782313 endingPage "224" @default.
• W2157782313 startingPage "219" @default.
• W2157782313 abstract "Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a standard first-line treatment for EGFR-mutant patients with non-small cell lung cancer (NSCLC). However, it remains unclear whether frontline EGFR TKIs affect subsequent chemo-sensitivity in EGFR-mutant patients. This study compared chemo-sensitivity in patients treated with post-TKI chemotherapy and first-line chemotherapy controls. Materials and methods This study included 203 EGFR-mutant patients. The study group contained 68 patients treated with chemotherapy after first-line EGFR-TKI and the control group contained 135 patients who received first-line chemotherapy. The response rate (RR), progression-free survival (PFS) and overall survival (OS) were assessed. Results In study group, the RR of chemotherapy was 13.2% compared with 34.1% in the control group (P = 0.002). The median PFS of chemotherapy in the control group was significantly longer than in the study group (6.9 vs. 3.9 months, P < 0.001), while the RR (76.5% vs. 68.9%, P = 0.259) and PFS (11.0 vs. 10.2 months) of EGFR-TKI were similar between first- and second-line treatment. Cox regression analyses indicated that prior EGFR-TKI treatment had a higher risk for disease progression during chemotherapy treatment [hazard ratio (HR) = 3.06; 95% CI = 2.12–4.42, P < 0.001]. Median overall survival was 31.7 months in the control group and 23.5 months in the study group (P < 0.001). The adjusted HR for death in the study group was 1.91 (95% CI = 1.33–2.76; P < 0.001). Conclusion In EGFR-mutant patients, frontline EGFR-TKI significantly reduced the sensitivity of subsequent chemotherapy compared with that of TKI-naïve frontline chemotherapy. These findings need to be validated in further randomized trials." @default.
• W2157782313 created "2016-06-24" @default.
• W2157782313 creator A5004598929 @default.
• W2157782313 creator A5006094015 @default.
• W2157782313 creator A5009003205 @default.
• W2157782313 creator A5011678564 @default.
• W2157782313 creator A5038306289 @default.
• W2157782313 creator A5039079516 @default.
• W2157782313 creator A5046162972 @default.
• W2157782313 creator A5072813027 @default.
• W2157782313 creator A5074151953 @default.
• W2157782313 creator A5082411167 @default.
• W2157782313 creator A5083650470 @default.
• W2157782313 creator A5091155603 @default.
• W2157782313 date "2014-11-01" @default.
• W2157782313 modified "2023-09-22" @default.
• W2157782313 title "Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor" @default.
• W2157782313 cites W2001595708 @default.
• W2157782313 cites W2018798914 @default.
• W2157782313 cites W2041436152 @default.
• W2157782313 cites W2048538776 @default.
• W2157782313 cites W2095618958 @default.
• W2157782313 cites W2096322101 @default.
• W2157782313 cites W2100093357 @default.
• W2157782313 cites W2111662961 @default.
• W2157782313 cites W2112602910 @default.
• W2157782313 cites W2113003672 @default.
• W2157782313 cites W2124967121 @default.
• W2157782313 cites W2128278369 @default.
• W2157782313 cites W2129360604 @default.
• W2157782313 cites W2132157071 @default.
• W2157782313 cites W2139248078 @default.
• W2157782313 cites W2154662831 @default.
• W2157782313 cites W2160982674 @default.
• W2157782313 cites W2166084034 @default.
• W2157782313 cites W2259557965 @default.
• W2157782313 cites W3108750466 @default.
• W2157782313 cites W53566393 @default.
• W2157782313 doi "https://doi.org/10.1016/j.lungcan.2014.09.008" @default.
• W2157782313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25263853" @default.
• W2157782313 hasPublicationYear "2014" @default.
• W2157782313 type Work @default.
• W2157782313 sameAs 2157782313 @default.
• W2157782313 citedByCount "17" @default.
• W2157782313 countsByYear W21577823132015 @default.
• W2157782313 countsByYear W21577823132016 @default.
• W2157782313 countsByYear W21577823132017 @default.
• W2157782313 countsByYear W21577823132018 @default.
• W2157782313 countsByYear W21577823132019 @default.
• W2157782313 countsByYear W21577823132020 @default.
• W2157782313 countsByYear W21577823132021 @default.
• W2157782313 countsByYear W21577823132022 @default.
• W2157782313 crossrefType "journal-article" @default.
• W2157782313 hasAuthorship W2157782313A5004598929 @default.
• W2157782313 hasAuthorship W2157782313A5006094015 @default.
• W2157782313 hasAuthorship W2157782313A5009003205 @default.
• W2157782313 hasAuthorship W2157782313A5011678564 @default.
• W2157782313 hasAuthorship W2157782313A5038306289 @default.
• W2157782313 hasAuthorship W2157782313A5039079516 @default.
• W2157782313 hasAuthorship W2157782313A5046162972 @default.
• W2157782313 hasAuthorship W2157782313A5072813027 @default.
• W2157782313 hasAuthorship W2157782313A5074151953 @default.
• W2157782313 hasAuthorship W2157782313A5082411167 @default.
• W2157782313 hasAuthorship W2157782313A5083650470 @default.
• W2157782313 hasAuthorship W2157782313A5091155603 @default.
• W2157782313 hasConcept C121608353 @default.
• W2157782313 hasConcept C126322002 @default.
• W2157782313 hasConcept C143998085 @default.
• W2157782313 hasConcept C207103383 @default.
• W2157782313 hasConcept C2776256026 @default.
• W2157782313 hasConcept C2776694085 @default.
• W2157782313 hasConcept C2778820342 @default.
• W2157782313 hasConcept C2779438470 @default.
• W2157782313 hasConcept C2780739268 @default.
• W2157782313 hasConcept C44249647 @default.
• W2157782313 hasConcept C71924100 @default.
• W2157782313 hasConcept C90924648 @default.
• W2157782313 hasConceptScore W2157782313C121608353 @default.
• W2157782313 hasConceptScore W2157782313C126322002 @default.
• W2157782313 hasConceptScore W2157782313C143998085 @default.
• W2157782313 hasConceptScore W2157782313C207103383 @default.
• W2157782313 hasConceptScore W2157782313C2776256026 @default.
• W2157782313 hasConceptScore W2157782313C2776694085 @default.
• W2157782313 hasConceptScore W2157782313C2778820342 @default.
• W2157782313 hasConceptScore W2157782313C2779438470 @default.
• W2157782313 hasConceptScore W2157782313C2780739268 @default.
• W2157782313 hasConceptScore W2157782313C44249647 @default.
• W2157782313 hasConceptScore W2157782313C71924100 @default.
• W2157782313 hasConceptScore W2157782313C90924648 @default.
• W2157782313 hasIssue "2" @default.
• W2157782313 hasLocation W21577823131 @default.
• W2157782313 hasLocation W21577823132 @default.
• W2157782313 hasOpenAccess W2157782313 @default.
• W2157782313 hasPrimaryLocation W21577823131 @default.
• W2157782313 hasRelatedWork W1548228303 @default.
• W2157782313 hasRelatedWork W1985488488 @default.
• W2157782313 hasRelatedWork W2017389411 @default.
• W2157782313 hasRelatedWork W2185481272 @default.

• next